<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01653405</url>
  </required_header>
  <id_info>
    <org_study_id>SDP 12-249</org_study_id>
    <nct_id>NCT01653405</nct_id>
  </id_info>
  <brief_title>Improving Anticoagulation Control in VISN 1</brief_title>
  <official_title>Improving Anticoagulation Control in VISN 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over 100,000 VHA patients receive anticoagulants (blood thinners) each year to prevent blood
      clots (including strokes). Too much anticoagulation increases the risk of serious or even
      fatal bleeding, and too little anticoagulation fails to protect the patient against blood
      clots. VHA anticoagulation clinics vary widely on how much time their patients spend in the
      therapeutic range, the range within which they are protected from clots but not at excessive
      risk of bleeding. Anticoagulation clinics can improve anticoagulation control by following
      several relatively simple procedures, including following-up promptly when patients are out
      of range and focusing on educating and supporting patients with poor control. In this study,
      the investigators will promote these practices at the anticoagulation clinics of the New
      England VA region, with a goal of improving anticoagulation control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Over 100,000 VA patients receive oral anticoagulation (AC) each year to prevent
      blood clots, including strokes. AC is safer and more effective when it is managed skillfully
      and therefore well-controlled. AC control can be measured using percent time in therapeutic
      range (TTR), the proportion of time when patients are sufficiently anticoagulated to prevent
      clots but not excessively anticoagulated (which increases the risk of bleeding). The
      investigators have shown that the anticoagulation clinics (ACCs) of the VA vary widely on
      TTR, from 40% (very poor control) to 70% (excellent control). Improving TTR in the VA would
      prevent thousands of adverse events, including strokes, major hemorrhages, and deaths. The
      investigators have further investigated the structures and processes of care that contribute
      to these wide disparities in TTR performance.

      Objectives: In this proposed study, the investigators will apply proven methods to change
      provider behavior and improve patient adherence and self-management. The goal will be to
      facilitate the adoption of these evidence-based practices in order to improve TTR in VISN 1.
      The investigators will accomplish this through a two-part intervention: 1) A
      clinician-focused intervention will utilize educational outreach, audit and feedback,
      internal facilitation, and external facilitation to promote improvements in four
      evidence-based processes of care. 2) A patient-focused intervention will utilize outreach, a
      group educational seminar, and motivational interviewing to educate patients with poor
      baseline anticoagulation control and promote behavior change.

      Methods: The clinician-focused intervention will use a Dashboard to measure site-level TTR
      and processes of care and an Algorithm for routine AC management. Both the Dashboard and the
      Algorithm are concrete representations of our main evidence-based recommendations to improve
      AC management. The investigators will promote their use through quarterly visits to the
      sites, which will include audit and feedback and educational outreach, and also provide
      external facilitation to address ways to improve these performance measures. The
      patient-level intervention will be delivered to the 25% of VISN patients with low TTR at
      baseline (&lt;50%). ACC staff will identify such patients using the Dashboard, and will send
      them an outreach letter inviting them to attend a brief educational seminar. All intervention
      patients, whether or not they attended the seminar, will receive follow-up management
      including motivational interviewing (MI) to address behavior change. The main outcome for Aim
      1 is change in site TTR over time, which will be compared between VISN 1 and non-VISN 1 sites
      using an interrupted time series. The main outcome for Aim 2 is change in patient-level TTR,
      for which intervention and control patients will be compared using a regression discontinuity
      analysis. Secondary outcomes will include site-level changes in processes of anticoagulation
      care (measured using automated data), costs and cost savings, and sustainability of changes
      over time.

      Anticipated Impact: The goal of this project is to increase TTR in VISN 1 to 75%, far higher
      than any other VISN. Such improvement in TTR is associated with greatly reduced rates of
      adverse events for patients. Improved TTR will save more money than our intervention will
      cost, in large part because of efficiencies of management and less-frequent follow-up for
      better controlled patients. At the conclusion of this regional project, the investigators
      will promote the spread of these interventions throughout the VHA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2014</start_date>
  <completion_date type="Actual">September 30, 2016</completion_date>
  <primary_completion_date type="Actual">September 30, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent time in therapeutic range</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Percent time in therapeutic INR range (TTR) is a summary measure of anticoagulation control over time. TTR will be measured in 6 month intervals at the level of the individual patient and also aggregated at the site level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of 56-day gaps in monitoring per patient-year among patients receiving anticoagulation with warfarin</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Gaps in INR monitoring have been associated with poor control and outcomes. We will be measuring the rate of such gaps at the level of the individual patient and also aggregated at the site level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days until follow-up after a high INR value (&gt;4.0)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>A prolonged interval until the next INR test after a high INR has been associated with poor control and outcomes. We will be measuring the number of days until the next INR value after a high INR at the individual patient and also aggregated at the site level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days until follow-up after a low INR value (1.5 or lower)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>A prolonged interval until the next INR test after a low INR has been associated with poor control and outcomes. We will be measuring the number of days until the next INR value after a low INR at the individual patient and also aggregated at the site level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean INR value among patients with an INR target of 2-3</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Mean INR value is a proxy measure for the actual target range that was used. If the clinician is truly attempting to achieve an INR of 2.5, then the mean INR should be very close to that over time, although individual values may be higher or lower. A mean INR value below 2.3 or above 2.7 is associated with poor anticoagulation control. We will be measuring the mean INR value at the individual patient and also aggregated at the site level.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Anticoagulants</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the top 75% of TTR at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the bottom 25% of TTR at baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Outreach, Education, and Motivational Interviewing</intervention_name>
    <description>Patients in the bottom 25% of TTR at baseline will receive an outreach message delivered at a routine care visit. The outreach message will inform them that their control is poor and this puts them at risk for bad outcomes. They will be offered an invitation to attend an education session to learn more about how to self-manage warfarin therapy. This session will be delivered by local clinical staff, using materials that we will provide. Finally, we will educate local clinical staff in the use of motivational interviewing (MI) and will provide a manual to help them deliver MI-based care. They will be asked to deliver MI-based care specifically to patients in the intervention group.</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients receiving long-term oral anticoagulation with warfarin within the VA New
             England Region (&quot;VISN 1&quot;)

        Exclusion Criteria:

          -  Patients with valvular heart disease, who may have an INR target range other than 2-3.
             This usually represents between 10-15% of patients receiving anticoagulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann M. Borzecki, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA</name>
      <address>
        <city>Bedford</city>
        <state>Massachusetts</state>
        <zip>01730</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rose AJ, McCullough MB. A Practical Guide to Using the Positive Deviance Method in Health Services Research. Health Serv Res. 2017 Jun;52(3):1207-1222. doi: 10.1111/1475-6773.12524. Epub 2016 Jun 28. Review.</citation>
    <PMID>27349472</PMID>
  </results_reference>
  <results_reference>
    <citation>Rose AJ, McCullough MB, Carter BL, Rudin RS. The Clinical Pharmacy Specialist: Part of the Solution. J Gen Intern Med. 2017 Apr;32(4):375-377. doi: 10.1007/s11606-016-3958-x. Epub 2016 Dec 19.</citation>
    <PMID>27995429</PMID>
  </results_reference>
  <results_reference>
    <citation>Rose AJ, Hylek EM, Berlowitz DR. Measuring and Improving Quality of Oral anticoagulation for Veterans. Federal practitioner : for the health care professionals of the VA, DoD, and PHS. 2013 Mar 1; 1(3):34-36.</citation>
  </results_reference>
  <results_reference>
    <citation>Rose AJ. Warfarin: not dead yet. J Gen Intern Med. 2014 Mar;29(3):425-6. doi: 10.1007/s11606-013-2708-6.</citation>
    <PMID>24249115</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim B, Shaikh OA, Rose AJ. Examining warfarin dosing decisions to improve anticoagulation management. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians. 2014 Sep 1; 30(5):168-174.</citation>
  </results_reference>
  <results_reference>
    <citation>McCullough MB, Solomon JL, Petrakis BA, Park AM, Ourth H, Morreale AP, Rose AJ. Balancing collaborative and independent practice roles in clinical pharmacy: a qualitative research study. Ann Pharmacother. 2015 Feb;49(2):189-95. doi: 10.1177/1060028014561473. Epub 2014 Nov 26.</citation>
    <PMID>25429093</PMID>
  </results_reference>
  <results_reference>
    <citation>McCullough MB, Petrakis BA, Gillespie C, Solomon JL, Park AM, Ourth H, Morreale A, Rose AJ. Knowing the patient: A qualitative study on care-taking and the clinical pharmacist-patient relationship. Res Social Adm Pharm. 2016 Jan-Feb;12(1):78-7; quiz 88-90. doi: 10.1016/j.sapharm.2015.04.005. Epub 2015 Apr 27.</citation>
    <PMID>26004019</PMID>
  </results_reference>
  <results_reference>
    <citation>Razouki Z, Ozonoff A, Zhao S, Jasuja GK, Rose AJ. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range. Circ Cardiovasc Qual Outcomes. 2014 Sep;7(5):664-9. doi: 10.1161/CIRCOUTCOMES.114.000804. Epub 2014 Sep 2.</citation>
    <PMID>25185245</PMID>
  </results_reference>
  <results_reference>
    <citation>McCullough MB, Chou AF, Solomon JL, Petrakis BA, Kim B, Park AM, Benedict AJ, Hamilton AB, Rose AJ. The interplay of contextual elements in implementation: an ethnographic case study. BMC Health Serv Res. 2015 Feb 14;15:62. doi: 10.1186/s12913-015-0713-7.</citation>
    <PMID>25890333</PMID>
  </results_reference>
  <results_reference>
    <citation>GÃ¶ren JL, Rose AJ, Engle RL, Smith EG, Christopher ML, Rickles NM, Semla TP, McCullough MB. Organizational Characteristics of Veterans Affairs Clinics With High and Low Utilization of Clozapine. Psychiatr Serv. 2016 Nov 1;67(11):1189-1196. Epub 2016 Jun 15.</citation>
    <PMID>27301765</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anticoagulants</keyword>
  <keyword>pharmacists</keyword>
  <keyword>quality improvement</keyword>
  <keyword>quality of health care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 26, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

